Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen Sells 500 Shares

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen sold 500 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $42.65, for a total value of $21,325.00. Following the sale, the director now owns 78,333 shares in the company, valued at approximately $3,340,902.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ AMPH traded down $0.18 during trading hours on Wednesday, reaching $42.04. 478,077 shares of the stock were exchanged, compared to its average volume of 428,214. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of 14.55, a P/E/G ratio of 0.87 and a beta of 0.82. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.72 and a current ratio of 2.18. Amphastar Pharmaceuticals, Inc. has a 52 week low of $38.43 and a 52 week high of $67.66. The stock’s fifty day simple moving average is $41.89 and its 200 day simple moving average is $49.87.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Wednesday, May 8th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.20. The business had revenue of $171.84 million for the quarter, compared to the consensus estimate of $171.13 million. Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. Sell-side analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.6 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on AMPH shares. JPMorgan Chase & Co. started coverage on Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price objective on the stock. StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, May 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, May 22nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $66.00.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC grew its position in Amphastar Pharmaceuticals by 0.8% during the fourth quarter. Exchange Traded Concepts LLC now owns 21,440 shares of the company’s stock worth $1,326,000 after buying an additional 169 shares in the last quarter. Quadrant Capital Group LLC grew its position in Amphastar Pharmaceuticals by 27.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after buying an additional 223 shares in the last quarter. Bridge City Capital LLC grew its position in Amphastar Pharmaceuticals by 0.8% during the first quarter. Bridge City Capital LLC now owns 34,773 shares of the company’s stock worth $1,527,000 after buying an additional 275 shares in the last quarter. Nations Financial Group Inc. IA ADV grew its position in Amphastar Pharmaceuticals by 2.7% during the first quarter. Nations Financial Group Inc. IA ADV now owns 14,923 shares of the company’s stock worth $655,000 after buying an additional 399 shares in the last quarter. Finally, Texas Permanent School Fund Corp boosted its holdings in shares of Amphastar Pharmaceuticals by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 32,704 shares of the company’s stock valued at $1,436,000 after purchasing an additional 424 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.